Over the past decade, there has been a notable surge in research dedicated to unraveling the intricate role of tight junction proteins in blood–brain barrier (BBB) damage associated with ischemic stroke. This bibliometric analysis explores the expansive landscape of occludin research, a key tight junction protein, during the years 2000–2023, shedding light on the global scientific contributions, collaborations, and emerging trends in this critical area of stroke pathogenesis. China and the United States emerge as significant contributors, underscoring their prominence in advancing our understanding of tight junction proteins. Occludin, identified as a linchpin in regulating BBB integrity, proves to be a pivotal player, with implications extending to the diagnosis of hemorrhagic transformation in ischemic stroke. This study identifies occludin as a potential biomarker, offering promise for early diagnosis and paving the way for novel diagnostic strategies. The analysis highlights the necessity for a more comprehensive exploration of tight junction proteins, including occludin and claudin‐5, particularly in the context of acute cerebral ischemia. The unique healthcare landscape in Kazakhstan adds urgency to the call for further scientific research in this region, emphasizing the need for tailored investigations to address specific regional challenges. This comprehensive overview not only delineates the current state of occludin research but also signals the direction for future investigations. The identified knowledge gaps and emerging trends provide a roadmap for researchers and policymakers alike, with implications for both scientific discourse and clinical practice. Moving forward, a deeper understanding of tight junction proteins, informed by the insights gleaned from this study, holds the potential to shape targeted therapeutic interventions and diagnostic strategies, ultimately contributing to advancements in global stroke care.

Study Evaluation: The bibliometric analysis of the published results of the alpha‐synuclein ( α ‐syn) detection study in the peripheral tissues of patients with Parkinson’s disease was carried out by us to study scientific activity and scientific productivity, to measure the quantitative and qualitative characteristics of scientific publications, author productivity, and citation of works, as well as the degree of interrelation between authors, journals, institutes, and countries. Purpose: This study is aimed at bibliometrically analyzing the results of studies on the detection of α ‐syn in peripheral tissue biopsy of patients with Parkinson’s disease from 2013 to 2023. Methods: The data was extracted from the Scopus database collection using an inclusive search strategy. Performance analysis and science mapping were conducted using RStudio v.4.3.1 with the bibliometrix R‐package. The analyzed data encompassed trends in publication and citation and the identification of leading institutions, primary sources, authors, and collaborative countries. Results: A total of 124 relevant studies from 53 different sources were thoroughly analyzed. The analysis included the materials of 843 authors, which together gave an impressive average of 37.67 citations per document over the past decade. The annual growth rate in this area of research, according to calculations, was 10.84%, indicating a steady increase in the number of publications over the study period. The huge volume of research results is highlighted by the inclusion of 231 unique keywords of authors. Conclusion: Studies on the detection of pathological α ‐syn in peripheral tissues for early morphological verification of the diagnosis of Parkinson’s disease are relevant in clinical neurology. α ‐syn detected in the skin biopsy of patients on the basis of this study and data from the world literature meets the requirements for biomarkers.

Актуальность. Немоторные проявления при болезни Паркинсона (БП) дебютируют задолго до манифестации двигательных нарушений. Распространенность частоты встречаемости немоторных симптомов (НМС) при БП колеблется от 70 до 100% пациентов. К часто встречающимся НМС при БП относятся: когнитивные нарушения, гипосмия, быстрое движение глаз (REM-rapid eye movement), расстройство поведения во сне (RBD-REM sleep behavior disorder), депрессия, запоры и расстройства мочеиспускания. Своевременная диагностика НМС при БП способствует ранней терапевтической коррекции. В данной статье рассматриваются НМС при болезни Паркинсона у пациентов города Актобе. Цель. Изучить частоту, структуру истепень выраженности НМС у пациентов на различных стадиях БП. Материалы и методы. Дизайн исследования: одномоментное поперечное. Исследование проводилось с мая 2019 года по июнь 2021 г. Исследование одобрено на заседании локального этического комитета Западно-Казахстанского Медицинского Университета г. Актобе, протокол № 4 от 17 мая 2019 года. Для оценки НМС применялась 1-ая часть шкалы MDS-UPDRS-немоторные аспекты повседневной жизни (nM-EDL). Данная часть шкалы оценивает влияние немоторных симптомов болезни Паркинсона на повседневную активность пациентов. Использовали следующие статистические критерии: Шапиро-Уилка, описательные статистики: медиана Me, нижний и верхний квартиль, стандартное отклонение. Корреляционный анализ проводился с помощью непараметрического критерия Спирмена для двух линейных переменных. Результаты и обсуждение: 1. У всех пациентов с БП отмечаются НМС легкой степени выраженности со средним баллом 7,5 по шкале MDS UPDRS-1. 2. Из всех НМС более выраженными оказались когнитивные нарушения (89,5%) и тревожность (89,5%); наименее выражены симптомы дофаминовой регуляции и нарушения мочеиспускания - в 4,4% и 2,9% случаев соответственно. 3. Установлено наличие положительной связи средней тесноты между шкалой MDS–UPDRS-1(nM-EDL) и продолжительностью заболевания (r=0,5, p<0,05). Таким образом, при прогрессировании БП происходило нарастание выраженности НМС. Заключение. Трудности диагностики НМС при БП обусловлены акцентированием внимания неврологов на моторных проявлениях БП. При этом, НМС являются «невидимой» частью айсберга, требующими первоочередного внимания врача. Использование шкалы MDS–UPDRS-1 (nM-EDL) врачами-неврологами будет способствовать своевременному выявлению НМС, соответствующей терапевтической коррекции и динамическому наблюдению за выраженностью НМС. Relevance. Non-motor manifestations in Parkinson's disease (PD) make their debut long before the manifestation of motor disorders. The prevalence of the frequency of non-motor symptoms (NMS) in PD ranges from 70 to 100% of patients. Common NMS in PD include: cognitive impairment, hyposmia, rapid eye movement (REM-rapid eye movement), sleep behavior disorder (RBD-REM sleep behavior disorder), depression, constipation and urination disorders. Timely diagnosis of NMS in PD contributes to early therapeutic correction. This article discusses NMS in Parkinson's disease in patients of the city of Aktobe. The aim of study: to investigate the frequency, structure and severity of NMS in patients at various stages of PD. Materials and methods: This study is a fragment of the dissertation work "Immunohistochemical markers of degenerative diseases of the nervous system". Study design: single-stage transverse. The study was conducted from May 2019 to June 2021. The study was approved at the meeting of the local Ethics Committee of the West Kazakhstan Medical University in Aktobe, Protocol No. 4 of May 17, 2019. The 1st part of the MDS-UPDRS scale-non-motor aspects of everyday life (nM-EDL) was used to evaluate the NMS. This part of the scale evaluates the effect of non-motor symptoms of Parkinson's disease on the daily activity of patients. The following statistical criteria were used: Shapiro-Wilka, descriptive statistics: median Me, lower and upper quartile, standard deviation. Correlation analysis was performed using Spearman's...